MNPR

Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel radiopharmaceuticals for oncology and a treatment for Wilson Disease, a rare genetic disorder. Its product pipeline includes MNPR-101-Zr for imaging advanced solid tumors, and MNPR-101-Lu and MNPR-101-Ac for therapeutic applications in oncology, alongside ALXN1840, a late-stage investigational drug for Wilson Disease. The company operates primarily in the United States and builds its drug development pipeline through in-house efforts and licensing of therapeutics.